Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from China Longevity Group Co. Ltd. ( (HK:1863) ) is now available.
China Longevity Group Company Limited reported modest top-line growth for the year ended 31 December 2025, with revenue rising 3.4% to RMB1,205.0 million and gross profit up 3.2% to RMB209.3 million. The group remains focused on sustaining profitability from its manufacturing and industrial activities in mainland China, leveraging its existing asset base and operational footprint.
Despite higher revenue and steady gross margins, profitability weakened as profit attributable to owners of the company fell to RMB44.3 million and finance costs more than doubled, weighing on earnings. The results highlight pressure from rising financing and operating expenses, which could constrain margin expansion and signal a more challenging environment for the company’s future earnings quality and capital structure management.
More about China Longevity Group Co. Ltd.
China Longevity Group Company Limited is a Cayman Islands–incorporated company listed in Hong Kong, operating through a group structure focused on manufacturing and related industrial operations in mainland China. The group generates revenue primarily from the sale of its products, with profitability driven by gross margin management and cost control across its subsidiaries.
Find detailed analytics on 1863 stock on TipRanks’ Stock Analysis page.